Company Overview and News

 
Laurentian Bank: Is The Recent Pullback A Good Buying Opportunity?

2018-10-15 seekingalpha
Shares of Laurentian Bank (OTCPK:LRCDF) (TSX:LB) have pulled back by as much as 33% in the past 3 years as it faces several headwinds. These headwinds include net interest margin compression and elevated non-interest expenses. The bank should be able to offset these headwinds thanks to: (1) anticipated rate hikes in Canada that should support its NIM expansion, (2) high-quality mortgage portfolio that should help keep its provision for credit losses low, and (3) improvements in Common Equity Tier 1 ratio.
RY RY LB

63
Q3 Portfolio Review

2018-10-05 seekingalpha - 1
This is the third quarter review of my retirement income portfolio. It was a very active quarter that included a final pension rollover to my IRA. About half of the rollover funds have been deployed. Some existing positions were trimmed to take profit and to diversify. In recent weeks, I've written articles about the 19 new positions, so this review will be a brief summary.
TXN CNUTF XOM RDSB ENB OPRF RDSA FTS WMT BCE CSCO ABBV DUKH BAMGF SO UPS MAIN TYT KMB CMI ENB MFC RY 0945 BNS JNJ ITW RYDBF 7203 WPC SPG ABBV MSFT QCOM PFE CLX CDUAF BAMKF NNN SOJA TM ADP SKT EPD TD ETN BNS MSCA AAPL BIP RYDAF TD CSCOI BAM BEP CU VTR IBM RDS.B RY RDS.A TNTTF APLE O DUK FDX TOYOF MSCA.CL BLK HP PEP ADPVV FTS PPL MFC

107
Jane's August Dividend Increases And Income Tracker - Retirement Accounts

2018-09-28 seekingalpha
This is the sixth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $689.45.
GIS WBA ENB OPRF WMB SCHF JCI HSY ABBV MMM POL MO DUKH GD BAC TRV GILD MAIN CMI ENB RY BNS JNJ ITW VZ WPC ABBV MSFT ADM PFE PM PFBC IRET CTL OXLCM OXLCO TD ETN OXLCN BNS BAC MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF AFL ORI PPL

4
Royal Bank Of Canada: Time To Buy?

2018-09-27 seekingalpha
Royal Bank has been trading in a sideways range for several months, but looks poised to break out of this recent trading range.
WFCNP RBCDF MS WFC RY RY

61
Buy This 3.4% Yielding Dividend Aristocrat With A Century-Long Dividend Track Record

2018-09-22 seekingalpha - 1
Together with its Canadian peers, it is a core holding in my dividend growth portfolio and one I will substantially increase over the years.
BAC C RY TNTTF BMO TD BNS BAC BMO RY BNS JPM TD

5
Buy This Canadian Bank With A 6% Yield At 52-Week Lows

2018-09-18 seekingalpha
Improving its CET 1 and Tier 1 ratios have positioned it for even slower growth in 2019-2020.
BMO RY RY TNTTF BNS LRCDF BMO LB TD TD BNS

 
Building Your Pension With RBC

2018-09-06 seekingalpha
The purpose of any pension is the ability to generate income. It’s not a pension if you don’t get paid.
RY RY

 
Royal Bank of Canada (RY) Management Presents at Scotiabank Financials Summit Conference (Transcript)

2018-09-05 seekingalpha
All right. Ladies and gentlemen, we are ready to get back to work here with our next guest. Very pleased to welcome to the stage Mr. Dave McKay, President and Chief Executive Officer of the Royal Bank of Canada. This is a position that he has held since August 2014, with Dave having first joined the bank in 1988. Sir?
RY RY CYN ACDVF AC

36
The Zacks Analyst Blog Highlights: Royal Bank of Canada, Bank of Montreal and Bank of Nova Scotia

2018-09-04 zacks
Chicago, IL – September 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Royal Bank of Canada (RY - Free Report) , Bank of Montreal (BMO - Free Report) and The Bank of Nova Scotia (BNS - Free Report) .
BMO BMQZF RBBN NWL RY RY BNS BMO AMD BNS

5
RY, BMO, BNS: Best Foreign Bank to Bet On Post Q3 Earnings

2018-08-30 zacks
Key foreign banks released earnings results in the last two weeks, providing a better understanding of the industry’s near-term prospects. After focusing on the one-time U.S. tax charges in the first half of this year, foreign banks shifted attention to the Fed’s “gradual” rate hike decision.
BMO BMQZF RY RY BNS BMO BNS

 
Royal Bank Of Canada: Outstanding Quarter - Expect More

2018-08-25 seekingalpha
Royal Bank of Canada delivered another outstanding quarter. Double-digit earnings growth beat expectations even as the company strengthens its balance sheet and credit losses decrease.
RY RY RBCDF

5
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of Aug 27

2018-08-25 seekingalpha
Royal Bank and CIBC came through for investors with their second raises of the year last week.
RY RY BNS CM BNS

 
Royal Bank of Canada 2018 Q3 - Results - Earnings Call Slides

2018-08-22 seekingalpha
The following slide deck was published by Royal Bank of Canada in conjunction with their 2018 Q3 earnings call.
RY RY

16
Royal Bank of Canada (RY) CEO Dave McKay on Q3 2018 Results - Earnings Call Transcript

2018-08-22 seekingalpha
Royal Bank of Canada (NYSE:RY) Q3 2018 Earnings Conference Call August 22, 2018 8:00 AM ET
RY RY CYN 3772 DIS

109
Jane's July Dividend Increases And Income Tracker - Retirement Accounts

2018-08-21 seekingalpha - 2
This is the fifth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,610.61.
GIS WBA ENB OPRF WMB SCHF JCI HSY ABBV MMM POL MO DUKH GD BAC TRV GILD MAIN CMI ENB RY BNS JNJ ITW VZ WPC ABBV MSFT ADM PFE PM PFBC IRET CTL OXLCM OXLCO TD ETN OXLCN BNS BAC MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF AFL ORI PPL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...